- Home
- DDI vs URGN Comparison
DDI vs URGN Comparison
Compare DDI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- URGN
- Stock Information
- Founded
- DDI 2008
- URGN 2004
- Country
- DDI South Korea
- URGN United States
- Employees
- DDI N/A
- URGN N/A
- Industry
- DDI EDP Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- DDI Technology
- URGN Health Care
- Exchange
- DDI Nasdaq
- URGN Nasdaq
- Market Cap
- DDI 489.1M
- URGN 463.2M
- IPO Year
- DDI 2021
- URGN 2017
- Fundamental
- Price
- DDI $9.96
- URGN $4.24
- Analyst Decision
- DDI Strong Buy
- URGN Strong Buy
- Analyst Count
- DDI 4
- URGN 8
- Target Price
- DDI $20.50
- URGN $27.92
- AVG Volume (30 Days)
- DDI 35.8K
- URGN 2.4M
- Earning Date
- DDI 05-13-2025
- URGN 05-12-2025
- Dividend Yield
- DDI N/A
- URGN N/A
- EPS Growth
- DDI 9.79
- URGN N/A
- EPS
- DDI 2.37
- URGN N/A
- Revenue
- DDI $336,679,000.00
- URGN $91,871,000.00
- Revenue This Year
- DDI $8.25
- URGN $35.06
- Revenue Next Year
- DDI $3.39
- URGN $112.94
- P/E Ratio
- DDI $4.20
- URGN N/A
- Revenue Growth
- DDI 5.41
- URGN 8.98
- 52 Week Low
- DDI $8.88
- URGN $3.42
- 52 Week High
- DDI $18.21
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- DDI 49.68
- URGN 27.72
- Support Level
- DDI $9.82
- URGN $3.71
- Resistance Level
- DDI $10.00
- URGN $4.25
- Average True Range (ATR)
- DDI 0.41
- URGN 0.91
- MACD
- DDI -0.03
- URGN -0.45
- Stochastic Oscillator
- DDI 23.38
- URGN 9.87
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. Its market opportunity includes casual gaming globally, which includes slots, puzzles, cards, match three, and other similar games. Within the social casino segment of casual gaming, which includes free-to-play online slots, poker, table games, and bingo. Other games developed by the company are DoubleDown Fort, DoubleDown Classic, and Ellen's Road to Riches. The company has a presence in the international market, and it derives a majority of its revenue from the United States of America.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.